EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Published on September 4, 2012 at 8:07 AM · No Comments

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA® (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.    

INLYTA, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which are proteins that can influence tumor growth, vascular angiogenesis and progression of cancer (tumor spread).

"INLYTA offers physicians and their patients with advanced kidney cancer a new treatment option following prior treatment with sunitinib or a cytokine. INLYTA data demonstrate statistically significant improvement in progression free survival compared with sorafenib, and support the continued role for VEGFR-targeted therapy, following the first-line standard of care, SUTENT," said Dr. Bernard Escudier, Head of the Immunotherapy Unit, Department of Medical Oncology, Institut Gustave Roussy, France, who served as an investigator on this Pfizer-sponsored study and is a paid consultant to Pfizer Oncology.  

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post